168 related articles for article (PubMed ID: 36596983)
21. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
22. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
[TBL] [Abstract][Full Text] [Related]
24. Baseline [
Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
[TBL] [Abstract][Full Text] [Related]
25. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
[TBL] [Abstract][Full Text] [Related]
26. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
27. Does MRD have a role in the management of iNHL?
Giudice ID; Starza ID; Foà R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
[TBL] [Abstract][Full Text] [Related]
28. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
Tychyj-Pinel C; Ricard F; Fulham M; Fournier M; Meignan M; Lamy T; Vera P; Salles G; Trotman J
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):408-15. PubMed ID: 24435770
[TBL] [Abstract][Full Text] [Related]
29. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
[No Abstract] [Full Text] [Related]
31. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M
Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480
[TBL] [Abstract][Full Text] [Related]
32. Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma.
Boo SH; O JH; Kwon SJ; Yoo IR; Kim SH; Park GS; Choi BO; Jung SE; Cho SG
Nucl Med Mol Imaging; 2019 Aug; 53(4):263-269. PubMed ID: 31456859
[TBL] [Abstract][Full Text] [Related]
33. Outcome of patients with early-stage follicular lymphoma staged with
Ng SP; Khor R; Bressel M; MacManus M; Seymour JF; Hicks RJ; Wirth A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):80-86. PubMed ID: 30083824
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.
Le Dortz L; De Guibert S; Bayat S; Devillers A; Houot R; Rolland Y; Cuggia M; Le Jeune F; Bahri H; Barge ML; Lamy T; Garin E
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2307-14. PubMed ID: 20717826
[TBL] [Abstract][Full Text] [Related]
35. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
36. Significance of initial, interim and end-of-therapy
Xie M; Wang L; Jiang Q; Luo X; Zhao X; Li X; Jin J; Ye X; Zhao K
Cancer Cell Int; 2021 Jul; 21(1):394. PubMed ID: 34311728
[TBL] [Abstract][Full Text] [Related]
37. Prognostic values of baseline, interim and end-of therapy
Zhou Y; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Cancer Manag Res; 2019; 11():6871-6885. PubMed ID: 31413633
[TBL] [Abstract][Full Text] [Related]
38. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
39. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
Kim J; Song YS; Lee JS; Lee WW; Kim SE
Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
